|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's Range||2.75 - 3.15|
|52 Week Range||2.52 - 8.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET OLDWICK, N.J. , Nov. 8, 2018 /PRNewswire/ -- Q3 2018 and Recent Corporate Highlights: Completed $63.9 million upsized initial ...
THOUSAND OAKS, Calif. and OLDWICK, N.J., Nov. 5, 2018 /PRNewswire/ -- Amgen (AMGN) and Provention Bio, Inc. (PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (NRCD). Development efforts at Provention will be led by researchers with previous experience developing AMG 714.
OLDWICK, N.J., Oct. 23, 2018 /PRNewswire/ -- Provention Bio, Inc. (PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, announced today that it has completed enrollment in the Phase 1b clinical trial of PRV-300 in patients with moderate-to-severe ulcerative colitis (UC). Provention is developing PRV-300, an anti-TLR3 monoclonal antibody, to intercept upstream disease processes in UC patients.
OLDWICK, N.J. , Sept. 11, 2018 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced ...
Industry executive adds considerable financial expertise as audit committee chairperson OLDWICK, N.J. , Sept. 5, 2018 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical ...
OLDWICK, N.J. , Aug. 13, 2018 /PRNewswire/ -- Recent Corporate Highlights: Closed initial public offering of common stock on July 19, 2018 , generating $63.9 million in gross proceeds Expanded pipeline ...
- Provention strengthens its strategic platform in type 1 diabetes (T1D) interception and prevention - Dr. Rigby's leadership and expertise in T1D will enhance Provention's clinical development of T1D ...